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Summary  In  the  management  of  atrial  ﬁbrillation  (AF),  stroke  prevention  has  been  proved
to play  a  pivotal  role  in  addition  to  therapy  for  concomitant  diseases.  And,  hitherto,  antico-
agulation  by  warfarin  has  been  the  only  effective  choice  that  is  known  to  decrease  the  stroke
rate with  ∼70%  risk  reduction.  Although  the  evidence  has  been  rigid,  there  are  many  barriersDabigatran not to  make  warfarin  therapy  pervasive.  However,  the  principle  of  ‘‘KISS  (keep  it  short  and
simple)’’ seems  to  alter  our  situations.  Changing  the  complex  pharmacology  with  warfarin  into
the simple  pharmacology  with  new  anticoagulants  would  lead  us  to  a  new  paradigm,  where  the
old book  is  now  rewritten  by  a  new  language.
© 2011  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
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Introduction
to  be  more  than  1  million  in  Japan  [1,2]. This  ﬁgure  was
based  on  the  number  of  patients  with  persistent  and  perma-Atrial  ﬁbrillation  (AF)  is  one  of  the  most  common  arrhyth-
mias  associated  with  increased  mortality  and  morbidity.
Recent  studies  have  estimated  the  number  of  AF  patients
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doi:10.1016/j.jjcc.2011.04.001ent  AF,  and  therefore,  AF  patients  including  the  paroxysmal
ype  would  equal  to  or  exceed  2  million  people  in  Japan.
Although  the  precise  mechanisms  of  the  association
etween  AF  and  increased  risk  of  death  remain  to  be  elu-
idated,  AF  is  a strong  independent  risk  factor  for  stroke
3,4],  which  should  contribute  to  the  increased  mortality
nd  morbidity.  Cardiogenic  cerebral  infarction  with  AF  is
ore  severe  than  the  other  types  of  stroke  [5],  and  this  char-
Published by Elsevier Ltd. All rights reserved.
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cteristic  would  strengthen  the  position  of  stroke  prevention
n  the  management  of  AF  patients.  Randomized  studies
6,7]  including  the  recent  J-RHYTHM  study  [8]  in  Japan
upport  this  clinical  attitude.  At  present,  there  is  no  clini-
al  evidence  that  pharmacological  and  non-pharmacological
nterventions  to  electrocardiograms  (AF  itself)  improved  the
ortality  and  morbidity  of  AF  patients.  Therapy  for  con-
omitant  diseases  to  AF  and  stroke  prevention  stratiﬁed  by
he  stroke  risks  is  the  most  important  for  the  prognosis  of  AF
atients.  In  this  review,  I  would  like  to  focus  upon  the  role
f  new  anticoagulants  in  AF  management.
aps between evidence and the real world
ince  the  1990s,  numerous  efforts  have  been  made  to
dentify  an  effective  therapy  for  stroke  prevention  in  AF
atients.  Before  then,  we  encountered  two  troublesome
linical  problems.  One  was  regarding  risk  stratiﬁcation,
nd  the  other  the  method  for  medical  intervention.  Many
andomized  clinical  studies,  their  meta-analyses,  and  obser-
ational  studies  have  solved  these  problems  [9—11]. These
tudies  apparently  seemed  to  transform  our  complex  clini-
al  situations  into  a  simple  framework,  which  is  composed
f  a  simple  tool  of  warfarin  combined  with  a  simple  strati-
cation  of  CHADS2 scoring  system.  Simplicity  has  been  well
nown  to  be  required  for  solving  many  social  and  personal
roblems,  which  is  known  as  ‘‘the  principle  of  KISS  (keep  it
hort  and  simple).’’  Actually,  this  principle  seemed  to  work
ell  in  stroke  prevention  in  AF  patients,  as  demonstrated  by
 study  that  the  spread  of  antithrombotic  therapy  decreased
he  increasing  rate  of  stroke  in  AF  patients  [12].
However,  at  the  same  time,  we  know  well  that  the  usage
f  warfarin  is  far  from  the  ideal  state  that  we  anticipate.  A
eta-analysis  revealed  that,  even  in  AF  patients  with  a his-
ory  of  stroke/TIA,  the  prescription  rate  of  warfarin  reaches
nly  ∼50%  [13]. Also  in  Japan,  our  hospital-based  cohort
tudy  [14]  and  a  multicenter  study  [15]  reported  a  similar  ﬁg-
re  of  warfarin  prescription  rates  in  AF  patients  with  stroke
isks.  The  underuse  of  warfarin  in  AF  patients,  which  should
e  a  theme  for  cardiologists  to  overcome,  would  lead  to  the
act  that  ∼85%  of  AF  patients  experiencing  stroke  were  not
reated  with  warfarin  prior  to  stroke.
Although  efforts  should  be  made  to  overcome  this  impor-
ant  problem,  we  know  that  there  are  many  limitations  in
he  widespread  use  of  warfarin  for  all  physicians  and  all  AF
atients.  There  is  a  big  gap  between  the  ideal  image  and
ur  actual  real  world.  The  usage  of  warfarin  causes  many
ypes  of  mental  burdens  to  physicians,  patients,  and  the
amilies  of  the  patients.  For  physicians,  anxiety  for  major
emorrhages  and  inconvenience  coming  from  strict  dose
itration  would  cause  the  underuse  of  warfarin.  For  patients,
he  frequent  blood  tests  and  limitations  in  everyday  meals
ould  lead  to  the  reluctance  to  take  warfarin.  The  limita-
ions  in  meals  affect  also  the  patient’s  family  members  who
o  not  take  warfarin.  More  than  imagined,  these  factors,
hich  apparently  are  trivial  medical  problems  from  aca-
emic  viewpoints,  would  affect  all  the  people  related  to
F  and  make  a  big  gap  between  the  evidence  and  the  real
orld.
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he next stage from complexity to simplicity
t  would  be  useful  to  speculate  on  the  origins  of  the  mental
urdens  of  warfarin  to  healthcare  providers  and  patients.
s  mentioned  above,  most  of  the  burdens  would  result  from
he  instability  of  warfarin  effects.  The  instability  requires
requent  blood  testing,  strict  dose  titration,  limitations  in
eals,  and  also  leads  to  the  risk  of  major  hemorrhages.  What
auses  the  instability  of  warfarin  effects?  The  pharmacol-
gy  of  warfarin  itself  would  be  one  of  the  reasons.  Actually,
he  pharmacological  actions  of  warfarin  are  very  complex
Fig.  1).  Warfarin  causes  multiple  effects  on  the  production
f  the  4  coagulation  molecules  (II,  VII,  IX,  and  X factors  in
he  coagulation  cascade),  and  the  effects  are  indirect  and
ffected  by  many  factors  including  vitamin  K  intake,  drug
nteractions,  VKOR  genotype,  CYP  genotype,  and  unknown
actors.  If  this  complex  warfarin  pharmacology  produces  the
ental  burdens,  the  rifts  between  the  evidence  and  the
eal  world  would  not  be  bridged  only  by  warfarin  and  the
ducational  activities  by  healthcare  providers.  The  princi-
le  of  ‘‘KISS’’  would  again  support  the  movement  that  the
omplex  pharmacology  should  be  improved  into  a  simpler
harmacology  with  a  new  agent.
And  now,  we  have  a  new  tool,  a  direct  thrombin  inhibitor,
abigatran,  for  stroke  prevention  in  AF  patients  and  would
ave  more  tools  of  anti-Xa  inhibitors  [16—22]. The  princi-
le  of  ‘‘KISS’’  has  seemed  to  produce  new  substitutes  for
arfarin.  Because  these  drugs  affect  the  coagulation  cas-
ade  via  a  single  molecule  directly  (Fig.  1),  the  drug  effect
ould  not  vary  from  patient  to  patient  and  be  affected  by
ther  environmental  factors.  This  stability  of  drug  effect
ould  make  it  unnecessary  to  change  the  doses  frequently
y  blood  tests,  to  make  limitations  in  meals,  and  to  be  too
nxious  for  major  hemorrhages.  Not  only  for  those  reasons,
he  ‘‘KISS’’  principle  would  affect  our  medical  practice  more
han  expected.  With  these  drugs,  stroke  prevention  in  AF
atients  would  appear  to  be  on  the  next  stage  from  complex-
ty  inherent  to  warfarin  to  simplicity  with  direct  inhibitors,
 part  of  which  is  shown  in  a  recent  large-scale  clinical  trial
23].
ew world opened by dabigatran
he  RE-LY  trial  is  a  randomized  controlled  study  comparing
he  efﬁcacy  and  safety  of  a  new  anticoagulant,  dabiga-
ran,  with  a  well-established  agent,  warfarin,  for  stroke
revention  in  AF  patients  [23]. The  results  of  the  study
ere  immediately  published  in  the  New  England  Journal  of
edicine,  and  also  referenced  by  many  reviews  [16—22].
herefore,  this  review  does  not  refer  to  the  results  in  detail.
he  study  aimed  to  show  the  non-inferiority  of  dabigatran  to
arfarin,  but  it  unexpectedly  showed  signiﬁcant  superiority
f  dabigatran  (150  mg  bid)  without  losing  the  safety  proﬁle.
t  shows  clear  dose-response  relationships  of  dabigatran  for
troke  prevention  and  major  hemorrhages,  both  of  which  are
reat  concerns  for  all  physicians.
This  new  pharmacological  approach  has  opened  a  new
aradigm.  In  addition  to  the  scientiﬁc  results  that  we  could
ely  on,  the  RE-LY  trial  has  rewritten  the  book  on  the
ommon  knowledge  constructed  by  anticoagulation  with
arfarin.  Before  the  trial,  only  the  convenience  was  pur-
New  anticoagulants  3
arfarin  and  the  simple  pharmacology  of  new  anticoagulants.  VK,
e  P450.
system  of  CHA2DS2-VASc  [26], which  could  be  derived  from
the  modiﬁcation  of  CHADS2 score.  In  both  scoring  systems,
AF  patients  with  2  points  or  more  are  strongly  recommended
to  take  anticoagulation  for  stroke  prevention.  Because  more
risks  and  more  points  have  been  included  in  the  new  scoring
system,  the  same  threshold  score  of  2  points  would  imply
that  the  strategy  has  been  modiﬁed  to  lower  the  threshold
for  stroke  prevention  with  the  new  anticoagulation  therapy
(Fig.  2).
New anticoagulants appearing
The  RE-LY  trial  is  not  the  end  of  this  innovative  era.  Sev-
eral  new  anticoagulants  of  anti-Xa  inhibitors  are  coming
to  our  clinical  practice.  These  drugs  include  rivaroxaban,
apixaban,  and  edoxaban.  Recently,  a  global  randomized  con-
trolled  study,  the  ROCKET-AF  study,  has  demonstrated  the
non-inferiority  of  rivaroxaban  to  warfarin  for  stroke  pre-
Figure  2  A  comparison  of  strategy  between  CHADS2 score  andFigure  1  A  schema  showing  the  complex  pharmacology  of  w
vitamin K;  VKOR,  vitamin  K  epoxide  reductase;  CYP,  cytochrom
sued  by  the  new  drug,  but  the  fruits  are  far  beyond  what
we  anticipated.  The  ﬁrst  fruit  is  the  superiority  of  dabiga-
tran  to  warfarin  that  has  been  the  most  effective  drug  for
stroke  prevention  in  AF  for  more  than  several  decades.  This
is  a  truly  innovative  event.  The  second  fruit  is  our  renewed
knowledge  that  the  balance  between  stroke  and  hemor-
rhage  differs  among  drugs,  which  should  be  very  natural
but  has  been  obscured  for  a  long  time.  When  a  drug  shows
a  narrow  range  between  the  therapeutic  and  toxic  doses,
strict  medical  practice  for  stroke  prevention  might  lead  to
increased  rate  of  major  hemorrhages  (seesaw  relationships),
as  shown  in  many  clinical  studies  with  warfarin  [24,25].  How-
ever,  when  the  range  is  wide,  the  drug  could  decrease  the
stroke  rate  without  increasing  the  hemorrhage  rate,  and  this
would  be  the  case  with  dabigatran.  And,  the  last  fruit  is
the  mental  freedom  for  physicians  and  patients  from  the
‘‘straitjacket’’,  which  includes  frequent  blood  testing,  dose
titration,  anxiety  for  hemorrhages,  and  so  on.  These  fruits
would  make  smaller  our  present  gap  of  stroke  prevention
between  the  ideal  and  the  real.
Moreover,  a  new  paradigm  would  open  a  new  strategy.
During  an  era  with  warfarin,  CHADS2 scoring  system  has  been
a  well-ﬁtted  strategy  for  physicians  and  patients.  The  sys-
tem  could  discriminate  AF  patients  that  warfarin  effectively
works  upon,  on  the  balance  between  stroke  prevention  and
major  hemorrhages.  However,  at  present,  we  have  a  tool
with  a  wider  therapeutic  range,  dabigatran.  Particularly,  it  is
noteworthy  that  the  rate  of  intracranial  hemorrhages  under
dabigatran  was  almost  the  same  as  that  without  any  anti-
coagulation  therapy  [23], although  the  precise  mechanisms
are  still  unknown.  This  fact  alters  the  risk-beneﬁt  balance
for  stroke  prevention.  Without  increase  in  intracranial  hem-
orrhage,  more  AF  patients  could  beneﬁt  from  a  new  type
of  anticoagulation.  This  means  the  requirement  of  a  new
strategy  ﬁtted  for  the  new  anticoagulation  therapy.  A  new
guideline  by  the  European  Society  of  Cardiology  in  2010  has
clearly  demonstrated  this  trend  by  presenting  a  new  scoring
CHA2DS2-VASc  score.  In  both  scoring  systems,  AF  patients  with
2 points  or  more  are  recommended  for  anticoagulation  therapy.
Most patients  categorized  into  1  point  in  CHADS2 score  would
move to  2  points  in  the  new  CHA2DS2-VASc  score.
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ention  of  AF  patients  in  a  double-blinded  fashion.  The
VERROES  study  [27], comparing  the  effects  of  apixaban
ith  aspirin  in  AF  patients  not  suitable  for  warfarin,  demon-
trated  the  superiority  of  apixaban  to  aspirin  as  expected.
n  the  assumption  that  the  patient  backgrounds  in  the  AVER-
OES  study  were  quite  similar  to  those  in  the  RE-LY  trial,  it  is
ery  promising  that  the  annual  rates  of  stroke  and  intracra-
ial  hemorrhage  under  apixaban  were  very  similar  to  those
bserved  under  dabigatran.  Edoxaban  is  a  Japanese  agent
hat  is  now  under  a  global  phase  III  trial  of  ENGAGE  AF-TIMI
8  [28]. The  drug  has  proved  to  be  effective  for  prevention
f  venous  thromboembolism  [29]. These  drugs  are  different
rom  dabigatran  in  that  they  are  direct  anti-Xa  inhibitors,
nd  there  are  some  other  differences  in  their  half-lives  or
etabolisms  [30]. At  present,  it  is  unknown  whether  the
ifferent  pharmacological  and  pharmacodynamic  actions  of
everal  new  anticoagulants  would  lead  to  different  clinical
utcomes  in  stroke  prevention  in  AF  patients.  In  the  near
uture,  clinical  experiences  with  these  direct  thrombin  and
a  inhibitors  will  open  more  progress  and  discussion.
ossible problems in the next stage
ot  all  things  are  good  in  this  next  stage  with  new  antico-
gulants,  because  there  are  some  problems  to  be  solved.
he  new  drugs  have  been  used  in  many  AF  patients  enrolled
n  the  clinical  trials,  but  the  information  is  still  limited
n  our  real-world  AF  patients.  As  compared  with  the  long-
ccumulated  experience  with  warfarin,  we  should  know  that
e  do  not  know  everything  about  the  new  agents.  Particu-
arly  with  dabigatran,  the  number  of  Japanese  AF  patients
hat  have  taken  the  drug  is  too  small.
The  ﬁrst  concern  is  the  antidote.  With  warfarin,  our  long
xperience  provides  several  antidotes  when  patients  are  suf-
ering  from  major  hemorrhages  under  warfarin.
They  are  vitamin  K,  fresh-frozen  plasma,  or  activated
ecombinant  factor  VII.  However,  under  new  anticoagulants,
here  are  no  reliable  methods  known  to  reverse  the  anti-
oagulation.  The  second  concern  is  regarding  AF  patients
ith  renal  insufﬁciency.  The  blood  concentrations  of  the
ew  anticoagulants  are  more  or  less  dependent  on  renal
ecretion,  which  is  a  different  characteristic  from  warfarin.
herefore,  the  safety  proﬁle  of  the  drugs  could  not  be
pplied  to  patients  with  severe  renal  dysfunction.  The  third
oncern  is  the  adherence  of  AF  patients  to  the  new  drugs.
or  better  or  worse,  warfarin  therapy  could  be  monitored  by
hysicians.  This  monitoring  has  supported  the  adherence  of
atients  to  warfarin.  However,  the  efﬁcacy  of  the  new  drugs
s  totally  dependent  upon  the  conﬁdence  between  health-
are  providers  and  patients.  Although  this  situation  is  true
or  all  medications  other  than  warfarin,  we  could  not  predict
he  effects  of  switching  from  warfarin  to  the  newer  drugs  at
resent.
The  last  point  to  mention  is  the  medical  costs,  which
hould  be  taken  into  account  from  many  viewpoints.  These
re  drugs  not  for  curing  diseases,  but  for  preventing  dis-
ases,  and  therefore  patients  should  take  them  for  all  their
ives.  These  are  drugs  not  for  rare  diseases,  but  for  a  com-
on  disease,  AF,  which  will  be  more  prevalent  in  a  society
ith  increasingly  aged  people.  We  can  easily  predict  the
ncreasing  demand  of  the  drugs  from  a  medical  viewpoint.
[T.  Yamashita
owever,  medical  interventions  for  AF  and  its  related  dis-
ases  cannot  be  too  expensive  for  society,  where  AF  is
erely  one  of  the  many  medical  problems.  Therefore,  the
edical  cost  to  our  society  should  be  a matter  of  discussion
uring  the  widespread  introduction  of  the  new  anticoagu-
ants.  However,  we  have  to  walk  on  the  new  road  because
e  have  already  known  the  innovation  in  AF  management.
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